COMPANY:

Novigenix

"Novigenix...has been awarded EUR 1.8M through the new BRECISE IHI grant funded by the European Union (EU) research initiative focusing on revolutionizing cancer diagnostics, treatment, and monitoring through advanced multi-omics and artificial intelligence.The BRECISE consortium was launched last week in Madrid at its face-to-face kick-off meeting during the 40th meeting of the European Association of Urology Congress. The multi-stakeholder collaborative effort, co-funded by the Innovative Health Initiative (IHI) under the Horizon Europe program, aims to transform patient care by integrating Next-Generation Sequencing (NGS)-based biomarkers with AI-driven decision-making frameworks.BRECISE seeks to address critical challenges in oncology, particularly in prostate and bladder cancer, by accelerating the clinical validation of multi-modal biomarkers."

"Novigenix...has published a new study marking a significant milestone in advancing early colorectal cancer (CRC) detection through innovative immune system profiling. The groundbreaking research, “Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression,” has been published in the Journal for Immunotherapy of Cancer...Novigenix’s Liquid ImmunoTranscriptomic Platform LITOSeek™ addresses these limitations by capturing the host immune response to onset of oncogenesis as a sensitive and alternative approach for early CRC detection."

"Novigenix...announced the approval of a Eurostars grant for the MYeloid SIGNATUREs (MY-SIGNATURE) project. This prestigious grant, totaling a consortium budget of €1.75 million, will support the development of MYELO-SCAN, the world’s first liquid biopsy test designed to predict intratumoral myeloid-derived suppressor cell (MDSC) infiltration in metastatic castration-resistant prostate cancer (mCRPC) patients."

"Novigenix...will showcase its multimodal approach at the European Society for Medical Oncology (ESMO) 2024 conference. This is poised to revolutionize the landscape of oncology treatment and drug development. The new approach combines advanced immune profiling with cell-free DNA (cfDNA) analysis, providing a comprehensive view of the patient peripheral tumor and immune signals."

"The Novigenix platform is optimized for whole-blood RNA biomarkers, and mapping of the patient’s immune system response to disease and treatment. The platform integrates patient multi-modal data and leverages advanced artificial intelligence approaches to provide actionable insights and precision solutions for the optimization of the patient's therapeutic journey."

"Novigenix SA...announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society for Medical Oncology (ESMO) GI Congress (28 June – 1 July 2023 | Barcelona, Spain)."

"Novigenix SA...announced successful first closing of its $20 million Series B financing round with participation from existing and new investors...The proceeds will be utilized to fast track the clinical validation of Novigenix's second generation NGS-based liquid biopsy CRC screening assay, and development of new immunotherapy patient stratification assays."

"A study was conducted with 29 BRAF+ and high lactate hydrogenase MM patients, treated with anti-PD-1/CTLA-4 therapy (ipi+nivo). Whole blood Immuno-Transcriptome profiles were analyzed before and after 6 weeks of combination therapy on the LITOseek platform of Novigenix for discovery of response prediction biomarkers and monitoring of patients following treatment, with clinical benefit defined as Progression-Free Survival (PFS) ≥ 6 months. A panel of 119 genes were identified for prediction of clinical benefit from combination therapy with an area under the curve (AUC) of 0.98. Functional analysis in responsive patients suggest upregulation of gene clusters involved in ribosomal biogenesis and TCR signaling, and downregulation of interferon gene clusters. A panel of 114 biomarkers identified for patient monitoring during ICI therapy further indicate upregulated gene clusters involved in cell cycle, and enrichment of immune tolerance regulating genes."

"Novigenix SA...announced a Technology License Agreement with Royal Philips (‘Philips’) for development of new tissue biopsy Prostate cancer (PCa) Immuno-Transcriptomic tests to improve prostate cancer patient outcomes...Through this agreement Novigenix has access to Philips Intellectual Property on tumor-derived Immuno-Transcriptomic signatures for development and launch of commercial products."